Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
rubber dildos.
Popular Articles

British Veterinary AssociationGuide To Partnerships In Veterinary Practice, UK
Continuing efforts to help its members form lasting and profitable partnerships and pre-empt disputes in veterinary practice, the British Veterinary Association (BVA) has revised its "Guide to partnerships in veterinary practice". It will be of particular interest to vets buying into a partnership for the first time and will also be helpful to partners revising their existing agreement.
diet pills
Segregation Decreases Access To Surgical Care For Minorities, Study Finds
New research published in the June issue of the Journal of the American College of Surgeons reveals that in counties with the highest levels of segregation, an increase in the African-American or Hispanic population was associated with a decrease in the availability and use of surgical services and an increase in the number of emergency room visits. This research supports prior studies that have shown that minority groups in the United States have comparatively poorer access to a range of health care services, often resulting in late diagnosis of illness and delayed treatment.
News of the day
Critical Appraisal Of Continuous Glucose Monitoring Technology Is Focus Of Diabetes Technology & Therapeutics Supplement
Continuous Glucose Monitoring (CGM) devices represent a critical step toward achieving automated glucose measurement, offering people with diabetes a promising new tool for maintaining optimal glucose control. A comprehensive review of this rapidly changing field, featuring the most recent research findings and critical analysis, is the focus of a special supplement of Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. The supplement is available free online at http://www.liebertonline.com/dia
Sexual Health

Celleron Therapeutics And Astrazeneca Announce Personalised Medicine Collaboration In Cancer For The Development Of AZ's Leading HDAC Inhibitor

Celleron Therapeutics Ltd, the Oxford UK based specialist in the development of individually targeted cancer medicines, has secured exclusive rights to AstraZeneca plc"s lead histone deacetylase (HDAC) inhibitor (AZD 9468), for global development in conjunction with its proprietary "CancerNav" predictive biomarker platform. "CancerNav" specifically identifies those tumours which are most likely to respond to an individual cancer drug, thereby enabling a highly focussed clinical development and commercialisation programme, based on a closely linked diagnostic and therapeutic "personalised medicine" approach. Celleron will lead the clinical trial programme and plans to use "CancerNav" to identify tumours that undergo a favourable response to the drug. This strategy of targeting the drug to responsive tumours potentially allows for much more rapid clinical development and subsequent market entry. HDAC"s are a family of enzymes that control a wide variety of mechanisms involved with tumour cell growth and division, and HDAC inhibitors represent a new group of anti-cancer agents. However, because HDAC"s are ubiquitously expressed targets, the clinical utility of HDAC inhibitors has been historically difficult to determine. Celleron"s "CancerNav" platform has already identified a specific biomarker for HDAC responsive tumours. This will now be applied to AZD 9468 (now to be known as CXD101), enabling a rapid move to Phase I clinical study, using the biomarker to select patients that respond well to the drug. After extensive due diligence and based upon its world-leading cancer biology expertise, Celleron believe that CXD101 is an HDAC inhibitor with multiple points of positive differentiation from competing products. The combined benefit of a predictive biomarker applied to a drug with potentially class-leading properties means that CXD101 is more likely to demonstrate greater clinical value than other HDAC inhibitor based therapies. "Today"s announcement provides early and strong endorsement of our predictive biomarker platform, "CancerNav" and secures an immediate and strong partner to share in the future value of the product. It is the ideal partnership to leverage our clinical and biomarker expertise", commented Professor Nick La Thangue, founder of Celleron. "The clinical potential of CXD101, as mono and combination therapy, encompasses a range of different tumour types, which can now be identified through a biomarker analysis program which Celleron will conduct. We will apply learning from our biomarker platform to build a focussed clinical development program and are actively seek partnerships at later stages of development to ensure the thorough and timely development of promising products. Our extensive HDAC inhibitor know-how and clinical development expertise, coupled with our unique biomarker capability, "CancerNav", gives us singular competitive advantage". Under the terms of the agreement, full development and commercialisation rights to CXD101 pass to Celleron, including the right to sublicense. AstraZeneca will receive significant milestones, royalties and additional share of financial proceeds in the event of successful commercialisation by a third party. Celleron has furthermore granted to AstraZeneca the right to discuss the reacquisition of commercialisation rights at an appropriate future juncture. John Goddard, SVP of Strategic Planning and Business Development at AstraZeneca commented that; "We are very pleased to enter into this innovative and flexible agreement with Celleron Therapeutics. We have strong respect for Celleron and Oxford University"s unique skills in this specific field. AstraZeneca will benefit from the potential success of this drug in several ways and through partnership can do so without the need to commit internal R&D res". Professor David Kerr, Chief Medical Officer and Founder of Celleron, and Professor of Cancer Therapeutics at Oxford University added; "I am delighted that a company of AstraZeneca"s global stature in oncology has recognised the value and potential of our novel biomarker and clinical development expertise. Cancer is a large unmet medical need but there remain significant deficiencies in the traditional clinical trial paradigm. Celleron"s biomarker-driven clinical development and patient stratification capability overcomes many of the existing bottlenecks. Furthermore, this innovative transaction structure gives AZ and Celleron a very attractive combination of partnership and flexibility". AstraZeneca


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009